SAILIFE Sai Life Q3 FY25 results (Oct–Dec 2024) and concall
Sai Life Sciences delivered a robust performance in its first earnings call as a public company, characterized by strong double-digit revenue growth and significant margin expansion. The company is aggressively utilizing IPO proceeds to deleverage its balance sheet while simultaneously investing in capacity expansion (200 KL total addition) and land acquisition for future growth. Management emphasized a shift toward long-term value creation, targeting a 28-30% EBITDA margin steady state within 2-3 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 396 | 440 |
| EBITDA | 102 | 120 |
| Net profit | 42 | 54 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
